LYSOCLEAR is an enzyme therapy being developed for age-related macular degeneration (AMD) and Stargardt’s macular degeneration.

Age-related macular degeneration (AMD) is the leading cause of vision loss among people over the age of 50, affecting 20 million Americans. Stargardt’s macular degeneration is an inherited condition that robs children of their sight. LYSOCLEAR shows promise as a highly targeted treatment for both conditions. LYSOCLEAR has been extensively studied in a research setting, and findings suggest that LYSOCLEAR is safe and effective at destroying toxic vitamin A derived aggregates (A2E) that may cause these diseases.

Learn more

Development Progress

LYSOCLEAR has been extensively studied in buffer systems, cell culture models, and in vivo.

Preliminary Findings

LYSOCLEAR is safe and effective at breaking down toxic A2E, removing up to 10% with each dose.

Studied Mechanism

LYSOCLEAR selectively localizes to the lysosomes of RPE cells where A2E accumulates, and destroys it.

As a practicing ophthalmologist, it is heartbreaking to see my patients lose vision at any age -- old or young. There is a desperate need for new, effective drugs to treat vision loss. LYSOCLEAR holds great promise to help my patients with macular degeneration, both juvenile onset and age-related.

William Tucker, MD

The idea of upgrading lysosomes of cells with the ability to degrade age-associated molecular garbage could fundamentally change how we think about and treat numerous age-related diseases. LYSOCLEAR targeting A2E in macular degeneration is an excellent proof-of-concept for an entirely new field: enzyme augmentation therapy,

Aubrey de Grey, PhD

Latest News from LYSOCLEAR